Lacosamide, Serum or Plasma
Also known as: LACOSA SP
Use
Optimizes drug therapy and monitors patient adherence by quantifying lacosamide levels. Lacosamide is an anticonvulsant indicated for adjunctive treatment of partial-onset seizures; the therapeutic range is based on predose (trough) serum or plasma concentration at steady state, and adverse effects may include dizziness, fatigue, nausea, vomiting, blurred vision, and tremor.
Special Instructions
Not provided.
Limitations
This test was developed by ARUP Laboratories and has not been cleared or approved by the US Food and Drug Administration. It is performed in a CLIA-certified laboratory. No FDA clearance. Intended for clinical use only.
New York Approved
Methodology
Mass Spectrometry
Biomarkers
Lacosamide
Analyte
LOINC Codes
- 59297-2 - Lacosamide SerPl-mCnc
Result Turnaround Time
1-5 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.5 mL
Container
Plain red; Also acceptable: Lavender (K2 or K3 EDTA) or pink (K2 EDTA)
Collection Instructions
Timing of specimen collection: Pre‑dose (trough) draw at steady state concentration.
Storage Instructions
Refrigerated; Also acceptable: Room temperature or frozen.
Causes for Rejection
Whole blood; Gel separator tubes; light blue (citrate), or yellow (SPS or ACD solution).
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | Ambient: 72 hours |
| Refrigerated | 2 weeks |
| Frozen | 2 weeks |
Other tests from different labs that may be relevant